165 episodes

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

BioCentury This Week BioCentury

    • Science
    • 5.0 • 10 Ratings

BioCentury's streaming commentary on biotech industry trends, plus interviews with leading KOLs. For over 28 years, BioCentury has given biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; industry-leading business intelligence; and global conferences.

    Ep. 158 - CAR T Manufacturing & Orphan Drugs

    Ep. 158 - CAR T Manufacturing & Orphan Drugs

    New manufacturing systems for CAR Ts aren’t just about speed, Executive Director for Biopharma Intelligence Lauren Martz said on the latest BioCentury This Week podcast. Martz and colleagues discuss the safety, efficacy and access benefits from rapid manufacturing platforms, and how these systems are set to change the way CAR T cells are delivered to patients. BioCentury’s editors also analyze the state of incentives for orphan drug development as the Orphan Drug Act turns 40, how the FTC’s non-compete proposal could have unanticipated effects for biotech, and what solutions former FDA commissioners are proposing to battle misinformation about science.

    • 29 min
    Ep. 157 - 2023 Markets Outlook & Buyside Picks

    Ep. 157 - 2023 Markets Outlook & Buyside Picks

    Investors broadly agree that biotech indexes won’t revisit the lows seen last year, but they’ll need their portfolio companies to survive until the industry begins its comeback, said Director of Biopharma Intelligence Stephen Hansen on the latest BioCentury This Week podcast. Discussing key takeaways from BioCentury’s 2023 Financial Markets Preview, Hansen detailed reasons to be positive in the year ahead, but cautioned that the financing windows will continue to be narrow and companies without a material catalyst this year need to deploy all the tools at their disposal to stay alive. Hansen and colleagues also discussed the milestones buysiders expect to drive excitement this year, and the outlook for M&A and partnerships, including the impact of the Inflation Reduction Act on dealmaking.

    • 27 min
    Ep. 156 - JPM Highlights & Alzheimer's Takeaways

    Ep. 156 - JPM Highlights & Alzheimer's Takeaways

    A trio of billion dollar deals for late-stage and commercial assets featuring contingent value rights were among the highlights of the first day of the J.P. Morgan Healthcare Conference in San Francisco on Monday. BioCentury's editors discuss AstraZeneca's takeout of CinCor, Ipsen's buy of Albireo and Chiesi's acquisition of Amryt as well as other takeaways from JPM, the CERSI summit and the Neuroscience Innovation Forum. The team also discusses the latest in Alzheimer's.

    • 30 min
    Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends

    Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends

    The U.K. government is signaling that life sciences companies will be shielded from changes to an R&D tax relief policy that would otherwise leave small biotechs losing millions of pounds, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. Usdin and his BioCentury colleagues discuss the behind-the-scenes initiative by the U.K. BioIndustry Association to protect companies from being affected by serious unintended consequences of the policy changes as they continue to weather the bear market.
    BioCentury’s editors also assess documents released by Congress that shed light on Biogen's rationale for how it priced Alzheimer’s drug Aduhelm, trends in FDA’s 2022 approvals and what the editorial team is looking for in the year ahead.

    • 35 min
    Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery

    Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery

    Phase III results for resmetirom from Madrigal Pharmaceuticals are more than enough for a regulatory submission in non-alcoholic steatohepatitis, said BioCentury Director of Biopharma Intelligence Paul Bonanos. Bonanos and colleagues discuss what Madrigal got right in running its trial for the challenging NASH indication, and what’s next in the pipeline. BioCentury’s editors also assess highly anticipated, heavily scrutinized data from Moderna among other 4Q22 readouts from neoantigen programs, as well as translational highlights from BioCentury’s Distillery.

    • 19 min
    Ep. 153 - The Inflation Reduction Act

    Ep. 153 - The Inflation Reduction Act

    A strategy for navigating the Inflation Reduction Act is essential for every biopharma company, regardless of size or location, Washington Editor Steve Usdin said on a special edition of the BioCentury This Week podcast. Usdin and his BioCentury colleagues discuss why creating an IRA strategy is so complex, when and how CMS is going to set prices for drugs selected for scrutiny and what the chances are that the act can be repealed or modified.

    • 19 min

Customer Reviews

5.0 out of 5
10 Ratings

10 Ratings

Pretty Kitty 2 ,

Simone Fishburn!!!!

Simone Fishburn is so well spoken and such a tremendous host. Need more of her in our lives !!

Top Podcasts In Science

Hidden Brain
Jeremy Corbell, George Knapp, Cadence13 and Dark Horse Entertainment
Alie Ward
Neil deGrasse Tyson
Mike Carruthers / OmniCast Media / Cumulus Podcast Network
NPR

You Might Also Like

STAT
Timmerman Report
Biotech 2050
Matt Pillar
Andreessen Horowitz
Andreessen Horowitz